Three table terms behind one everyday word
Three rows in the US adult table relate to what most people call heartburn or indigestion. Dyspepsia is the medical word for indigestion. Gastroesophageal reflux disease (GERD) describes stomach contents coming back up into the food pipe. Gastritis means inflammation of the stomach lining; a footnote says that row also counts chronic, erosive and reflux gastritis. [1] The EU and Canadian documents use the same three terms. [2][3]
| Label term | Source and pool | Placebo | Wegovy® 2.4 mg |
|---|---|---|---|
| Dyspepsia | US Table 3, adults [1] | 3% | 9% |
| Dyspepsia | Canadian Table 4, STEP 1–3 [3] | 3.2% | 9.0% |
| Gastroesophageal reflux disease | US Table 3, adults [1] | 3% | 5% |
| Gastroesophageal reflux disease | Canadian Table 4 [3] | 3.0% | 5.4% |
| Gastritis | US Table 3, adults [1] | 1% | 4% |
| Gastroesophageal reflux disease | US Table 5, ages 12 and older [1] | 2% | 4% |
| All three | EU SmPC 4.8, STEP 1–4 [2] | not given | “common”, mainly during dose escalation |
How the leaflet words it, and a blank at 7.2 mg
The Medication Guide translates these into plain language: its list of the most common side effects in adults and children aged 12 and older includes heartburn and upset stomach, alongside belching, gas and feeling bloated. The text of section 6.1 also names hiccups among digestive reactions more frequent on the injection, without a percentage. For teenagers, Table 5 shows only reflux because it starts at 3%; the text says indigestion was also more frequent but gives no figure. [1]
The two 72-week trials of 7.2 mg have their own table, which lists a reaction only if at least 2% of the 7.2 mg group reported it and it was more frequent than in both other arms. Dyspepsia, reflux and gastritis are not on it, so there is no heartburn-type figure for the higher dose. [1] Reading that blank as “more” or “less” would go beyond what is written.
What larger studies add about reflux
A 2025 meta-analysis of 55 placebo-controlled randomised trials with more than 106,000 participants found GLP-1 medicines probably increased the risk of reflux disease (risk ratio 2.19), equal to about 4 extra cases per 1,000 people. The effect looked stronger in trials of people with overweight or obesity and with higher-dose, weight-loss formulations, though those subgroup differences were not statistically significant. [4]
A UK cohort of people with type 2 diabetes compared new users of GLP-1 medicines with new users of SGLT-2 inhibitors over about three years. Reflux disease was 27% more likely with GLP-1 medicines, an absolute difference of 0.7 per 100 people, and its complications were also more common. [5] The study could not account for diet and lifestyle, and it was not limited to semaglutide or to the Wegovy® dose.
Why reflux may happen: three layers
- In the label: semaglutide delays stomach emptying (section 12.2), and digestive reactions concentrate around dose increases. [1] The label does not say that slower emptying causes reflux.
- Proposed in research: the authors of the cohort study point out that delayed gastric emptying is a known risk factor for reflux disease, which is why they looked for a link. [5] That is a hypothesis the study set out to test, not a mechanism it proved.
- General background: NIH explains that reflux disease develops when the valve at the bottom of the food pipe weakens or relaxes when it should not, and lists obesity, pregnancy, smoking and a hiatal hernia among factors that affect it. [6]
Other causes of heartburn
NIH and MedlinePlus list medicines that can bring on or worsen heartburn, including calcium channel blockers and beta-blockers for blood pressure, sedatives such as benzodiazepines, some asthma medicines, tricyclic antidepressants, anti-inflammatory painkillers and progestin. [6][9] MedlinePlus advises talking to your provider if you think a medicine is the cause and never stopping one on your own. [9]
Section 12.3 of the Wegovy® label reports that semaglutide blood levels did not differ in a clinically significant way in people with chronic gastritis or reflux disease, a statement about absorption rather than symptoms. Section 5.6 says Wegovy® is not recommended in severe gastroparesis. [1]
Self-care that NIH describes
For reflux, NIH lists lifestyle changes a doctor may suggest: raising the head of the bed with a wedge or extra pillows under the head and upper back, stopping smoking, avoiding meals shortly before lying down, and changing eating habits. [7][8] Foods and drinks often linked to symptoms include citrus fruits and tomatoes, alcohol, chocolate, coffee and other caffeine, high-fat and spicy foods, and mint, and NIH suggests discussing your own triggers with your doctor. [8]
On medicines, NIH notes that antacids can relieve mild heartburn but should not be used every day or for severe symptoms without discussing them with a doctor, and that H2 blockers and proton pump inhibitors are available over the counter. [7] The Wegovy® label does not mention any of them; it asks you to tell your provider about every over-the-counter medicine you take, [1] so check with your pharmacist first.
Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- A burning feeling with squeezing, crushing or pressure in the chest
Contact: Emergency number right away; it may be a heart attack
MedlinePlus [9]
- Vomit with blood or coffee-ground material, or black, tarry stools
Contact: Urgent medical care
- Severe stomach-area pain that will not ease, sometimes reaching the back
Contact: Stop Wegovy® and call your provider right away
Medication Guide [1]
Today
At your next appointment
- Heartburn that is frequent or does not settle after a few weeks of self-care, or a cough or wheeze that lingers
Contact: Your provider at an appointment
MedlinePlus [9]
- A planned procedure under anaesthesia or deep sedation
Contact: Tell every provider involved that you use Wegovy®
Wegovy® section 5.10 [1]